150 related articles for article (PubMed ID: 32277005)
21. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
22. Plasma adrenal androgens and risk of breast cancer in premenopausal women.
Page JH; Colditz GA; Rifai N; Barbieri RL; Willett WC; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):1032-6. PubMed ID: 15184260
[TBL] [Abstract][Full Text] [Related]
23. Premenopausal plasma ferritin levels, HFE polymorphisms, and risk of breast cancer in the nurses' health study II.
Graff RE; Cho E; Lindström S; Kraft P; Willett WC; Eliassen AH
Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):516-24. PubMed ID: 24443403
[TBL] [Abstract][Full Text] [Related]
24. Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer.
Elfar GA; Ebrahim MA; Elsherbiny NM; Eissa LA
Oncol Res; 2017 Apr; 25(4):641-650. PubMed ID: 27983911
[TBL] [Abstract][Full Text] [Related]
25. Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer.
Bertrand KA; Rosner B; Eliassen AH; Hankinson SE; Rexrode KM; Willett W; Tamimi RM
Breast Cancer Res Treat; 2015 Jan; 149(2):479-87. PubMed ID: 25543181
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
27. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females.
Shaker OG; Elbaz EM
Asian Pac J Cancer Prev; 2020 Feb; 21(2):355-361. PubMed ID: 32102511
[TBL] [Abstract][Full Text] [Related]
28. Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women.
Shaker OG; Senousy MA
Clin Breast Cancer; 2019 Feb; 19(1):e220-e238. PubMed ID: 30309792
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
30. Low serum osteoprotegerin levels in premenopausal infertile women with low bone density: an association of relevance?
Norian JM; Zeitlian G; Adel G; Freeman RG; Santoro NF; Pal L
Fertil Steril; 2009 Feb; 91(2):542-8. PubMed ID: 18490014
[TBL] [Abstract][Full Text] [Related]
31. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
Eliassen AH; Tworoger SS; Mantzoros CS; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):161-4. PubMed ID: 17220346
[TBL] [Abstract][Full Text] [Related]
32. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
33. Erythrocyte membrane fatty acids and breast cancer risk: a prospective analysis in the nurses' health study II.
Hirko KA; Chai B; Spiegelman D; Campos H; Farvid MS; Hankinson SE; Willett WC; Eliassen AH
Int J Cancer; 2018 Mar; 142(6):1116-1129. PubMed ID: 29071721
[TBL] [Abstract][Full Text] [Related]
34. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
35. Bone metastases detection by circulating biomarkers: OPG and RANK-L.
Mercatali L; Ibrahim T; Sacanna E; Flamini E; Scarpi E; Calistri D; Ricci M; Serra P; Ricci R; Zoli W; Kang Y; Amadori D
Int J Oncol; 2011 Jul; 39(1):255-61. PubMed ID: 21491082
[TBL] [Abstract][Full Text] [Related]
36. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
37. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
[TBL] [Abstract][Full Text] [Related]
38. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
39. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer.
Zhang SM; Willett WC; Selhub J; Hunter DJ; Giovannucci EL; Holmes MD; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2003 Mar; 95(5):373-80. PubMed ID: 12618502
[TBL] [Abstract][Full Text] [Related]
40. Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Houghton SC; Eliassen AH; Zhang SM; Selhub J; Rosner BA; Willett WC; Hankinson SE
Breast Cancer Res Treat; 2019 Jul; 176(1):191-203. PubMed ID: 30955184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
